Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 10.91 +0.22 (+2.06%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 7 Next > Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? November 27, 2023 Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE) Via Benzinga Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus November 27, 2023 From Roivant Sciences Via GlobeNewswire 8 Analysts Have This to Say About Roivant Sciences November 14, 2023 Via Benzinga Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update November 13, 2023 From Roivant Sciences Via GlobeNewswire Roivant Sciences Earnings Preview November 10, 2023 Via Benzinga What 8 Analyst Ratings Have To Say About Roivant Sciences October 17, 2023 Via Benzinga Earnings Scheduled For November 13, 2023 November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. Via Benzinga Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors November 10, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 October 30, 2023 From Roivant Sciences Via GlobeNewswire It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy October 24, 2023 The market's dour reaction to Roivant Sciences' latest deal doesn't add up. Via The Motley Fool FSR Stock Alert: What to Know as Fisker Drops Prices October 23, 2023 Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV. Via InvestorPlace PINS Stock Pops as Stifel Upgrades Pinterest October 23, 2023 Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target. Via InvestorPlace Why Is Roivant Sciences (ROIV) Stock Up Today? October 23, 2023 ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. Via InvestorPlace Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space October 23, 2023 Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. Via Investor's Business Daily Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal October 23, 2023 Roche Holding AG (OTC: RHHBY) inked a deal to acquire Via Benzinga Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket October 23, 2023 Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set... Via Benzinga Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session October 23, 2023 U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. Via Benzinga Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant October 23, 2023 From Roivant Sciences Via GlobeNewswire Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer October 13, 2023 From Covant Therapeutics Via GlobeNewswire Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. October 04, 2023 The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. Via Investor's Business Daily 3 No-Brainer Growth Stocks to Buy in October October 01, 2023 These three top mid-cap stocks could be poised for a long-tailed growth spurt. Via The Motley Fool Why Immunovant Stock Is Bolting Higher Today September 27, 2023 The company may have best-in-class autoimmune disease therapy under its roof. Via The Motley Fool Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday September 27, 2023 Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... Via Benzinga Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst September 27, 2023 Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. Via Talk Markets Why Shares of Immunovant Are Soaring on Tuesday September 26, 2023 Immunovant sees strong potential for an autoimmune disorder therapy. Via The Motley Fool Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 26, 2023 Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... Via Benzinga Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday September 26, 2023 U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? September 26, 2023 Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)... Via Benzinga These 2 Biotech Stocks Are Bucking a Down Market Tuesday September 26, 2023 Stock index futures pointed to a lower open on Wall Street Tuesday morning. Via The Motley Fool Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results September 26, 2023 From Roivant Sciences Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.